Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
07/30/2020 07/31/2020 08/03/2020 08/04/2020 08/05/2020 Date
153(c) 150.29(c) 152.84(c) 154.85(c) 154.34(c) Last
6 638 127 5 342 109 3 618 435 3 260 042 2 476 460 Volume
-5.41% -1.77% +1.70% +1.32% -0.33% Change
More quotes
Financials (USD)
Sales 2020 23 813 M - -
Net income 2020 6 191 M - -
Net Debt 2020 11 888 M - -
P/E ratio 2020 23,0x
Yield 2020 1,93%
Sales 2021 25 735 M - -
Net income 2021 7 084 M - -
Net Debt 2021 9 711 M - -
P/E ratio 2021 19,8x
Yield 2021 2,08%
Capitalization 140 B 140 B -
EV / Sales 2020 6,37x
EV / Sales 2021 5,81x
Nbr of Employees 33 625
Free-Float 99,8%
More Financials
Company
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (47.6%): products for treating osteoporosis, diabetes, and growth problems; - oncology (17.4%); - veterinary medicine (12.8%); - cardiovascular diseases (9.2%); - neurology (7.4%): primarily drugs used in treating depression and schizophrenia; - immunology diseases (4. 
Sector
Pharmaceuticals
Calendar
08/13Ex-Dividende Tag
More about the company
Surperformance© ratings of Eli Lilly and Company
Trading Rating : Investor Rating :
More Ratings
Latest news on ELI LILLY AND COMPANY
08/05ELI LILLY AND : Empagliflozin meets primary endpoint in reducing risk of cardiov..
AQ
08/04ELI LILLY AND : U.S. to Launch Covid-19 Drug Research Starting With Eli Lilly Tr..
DJ
08/04ELI LILLY AND : Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COV..
AQ
08/03FOCUS : Next big COVID-19 treatment may be manufactured antibodies
RE
08/03REGENERON PHARMACEUTICALS : says antibody cocktail prevents and treats COVID-19 ..
RE
08/03ELI LILLY AND : Thinking about trading options or stock in Sorrento Therapeutics..
PR
08/03REGENERON PHARMACEUTICALS : Eli Lilly tests antibody drug to halt COVID-19 sprea..
RE
08/03ELI LILLY AND : Studies Experimental Covid-19 Drug in Nursing Homes
DJ
08/03ELI LILLY AND : Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COV..
PR
07/31ELI LILLY AND : & CO Management's Discussion and Analysis of Results of Operatio..
AQ
07/31ELI LILLY AND : Q2 2020 Earnings Presentation
PU
07/31ELI LILLY AND COMPANY : - Lilly Reports Second-Quarter Financial Results, Raises..
AQ
07/31ELI LILLY AND COMPANY : - Jardiance meets primary endpoint in reducing risk of c..
AQ
07/30Eli Lilly starts mid-stage study of COVID-19 treatment
RE
07/30ELI LILLY & CO : Results of Operations and Financial Condition, Financial Statem..
AQ
More news
News in other languages on ELI LILLY AND COMPANY
08/05ELI LILLY AND : Empagliflozin meets primary endpoint in reducing risk of cardiov..
08/04ELI LILLY AND : U.S. to Launch Covid-19 Drug Research Starting With Eli Lilly Tr..
08/04ELI LILLY AND : Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COV..
08/03FOCUS : Next big COVID-19 treatment may be manufactured antibodies
08/03REGENERON PHARMACEUTICALS : says antibody cocktail prevents and treats COVID-19 ..
More news
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 166,71 $
Last Close Price 154,34 $
Spread / Highest target 23,1%
Spread / Average Target 8,01%
Spread / Lowest Target -22,2%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY17.43%139 905
JOHNSON & JOHNSON0.93%390 711
ROCHE HOLDING AG1.04%299 337
PFIZER, INC.-1.86%213 583
MERCK & CO., INC.-10.24%206 068
NOVARTIS AG-17.36%184 831